News

Marketed with promises such as ‘smell better everywhere’ or ‘keep fresh all over’, some claim to offer up to 72 hours of ...
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis ...